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Angiotensin II (AngII) and its type receptor (AT1-R) play important roles in the development of cardiac
hypertrophy. Low level of high density lipoprotein (HDL) is also an independent risk factor for cardiac
hypertrophy. We therefore investigated in the present study whether HDL inhibits cardiac hypertrophy
relatively to inhibition of AngII and AT1-R in both in vitro and in vivo experiments. Stimulation of cultured
cardiomyocytes of neonatal rats with AngII for 24 h and infusion of AngII in mice for 2 weeks resulted in
marked cardiac hypertrophic responses including increased protein synthesis, enlarged sizes of cardio-
myocytes and hearts, upregulated phosphorylation levels of protein kinases and reprogrammed expres-
sion of specific genes, all of which were significantly attenuated by the treatment with HDL. Furthermore,
AngII-treatment induced upregulation of AT-R expression either in cultured cardiomyocytes or in hearts
of mice and HDL significantly suppressed the upregulation of AT1-R. Our results suggest that HDL may
abrogate AngII-induced cardiac hypertrophy through downregulation of AT1-R expression.
 2010 Elsevier Inc. All rights reserved.1. Introduction and effectively used in the treatment of not only hypertensionCardiac hypertrophy is not only an adaptative state before car-
diac failure, but also an independent risk factor for major cardiac
events [1]. It is thus very important to prevent and/or to suppress
the development of cardiac hypertrophy during various patholog-
ical stimulations. It has been previously shown that rennin–
angiotensin systems (RAS) including angiotensin II (AngII) and its
type 1 receptor (AT1-R) play a crucial role in the development of
cardiac hypertrophy [2–4]. Studies using primary cultured neona-
tal cardiomyocytes have demonstrated that AngII directly induces
cell enlargement and fetal gene expression [5,6]. When adminis-
tered systemically at suppressor doses, AngII induces myocardial
growth [7,8]. Continuous infusion of AngII in rats results in an in-
crease in left ventricular (LV) mass independently of its pressure-
elevating effects. Cardiac-specific overexpression of AngII in a
transgenic murine model leads to cardiac hypertrophy in the ab-
sence of hypertension [9]. These results clearly indicate that AngII
and AT1-R are critical to the development of cardiac hypertrophy.
Clinically, inhibitors for RAS such as AngII converting enzyme
inhibitors (ACEI) and AT1-R blockers (ARB) have been generallyll rights reserved.
of Cardiovascular Diseases,
oad, Shanghai 200032, China.
(Y. Zou), jbge@zs-hospital.but also cardiac hypertrophy. However, ACEI and ARB have severe
side effect in some patients. It is therefore requited to explore
whether there are other inhibitory factors for RAS.
High density lipoprotein (HDL) particles play a critical role in
preventing atherosclerosis through the function of reverse choles-
terol transport [10,11]. HDL cholesterol may also exert antioxidant
and anti-inflammatory effects in patients with heart failure
[12,13]. There has been study demonstrated that HDL is superior
to B-type natriuretic peptide as a marker of systolic cardiac dys-
function in an elderly general population [14]. Recently, it has been
indicated clinically that the low HDL levels are independent risk
factors for LV hypertrophy [15–17]. Furthermore, it has been sug-
gested that there is a cross-talk between RAS and clusters of lipo-
proteins [18–20]. HDL may reduce the hyperglycemia-induced
upregulation of the AT1-R in human aortic endothelial cells [21].
These data collectively suggest that HDL might play a role in inhi-
bition of RAS and thereafter in suppression of cardiac hypertrophy.2. Methods
2.1. Animal models
C57BL/6 mice were purchased from Shanghai Animal Adminis-
tration Center (Shanghai, China). AngII (200 ng/kg/min, Sigma–
Aldrich), and HDL (Calbiochem US and Canada, 400 ng/kg/min) were
continuously administered by Alzet osmotic minipumps (DURECT,
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protocols were approved by the Animal Care and Use Committee
of Fudan University and in compliance with ‘‘Guidelines for the Care
and Use of Laboratory Animals’’ published by the National Academy
Press (NIH Publication No. 85-23, Revised 1996).
2.2. Echocardiography and haemodynamic measurements
Transthoratic echocardiography was performed using 30 MHz
high frequency scanhead (VisualSonics Vevo770, VisualSonics Inc.
Toronto, Canada) [22]. All measurements were averaged for five
consecutive cardiac cycles and were carried out by three experi-
enced technicians who were unaware of the identities of the
respective experimental groups. Blood pressure (BP) was evaluated
as previously described [23,24]. Briefly, a micronanometer catheter
(Millar 1.4F, SPR 835, Millar Instruments, Inc. Houston, TX) was in-
serted into the right common carotid artery. The transducer was
connected to Power Laboratory System (AD Instruments, Castle
Hill, Australia) and BP was recorded.
2.3. Morphology and histological analyses
Excised hearts were weighed, perfused with PBS followed by 4%
polyformaldehyde for global morphometry and fixed in 10% forma-
lin for histological analysis. Paraffin embedded hearts were sec-
tioned at 4-lm thickness and stained with hematoxylin and
eosin (H–E). Cardiomyocytes were chosen from each section at a
high magnification, and cross sectional area (CSA) of cardiomyo-
cytes was measured by a video camera (Leica Qwin 3) attached
to a micrometer in 20 different randomly chosen points from each
cross section of LV free wall.
2.4. Cell culture and treatment
Neonatal rat cardiomyocytes were cultured in Dulbecco’s mod-
ified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS)
for 24 h and then in serum-free DMEM for 24 h. After pretreated
with HDL (100 lg/ml) for 60 min, AngII (1 lmol/l) or vehicle was
added to the cells. After 24 h incubation, cardiomyocytes were col-
lected and lysed for the further real-time RT-PCR analysis.
2.5. [3H] leucine incorporation
Cultured cardiomyocytes were incubated with [3H] leucine
(1 Ci/ml) in the presence of vehicle (Control), AngII (1 lmol/l),
HDL (100 lg/ml) or HDL plus AngII 48 h. Cells were then treated
with 5% trichloroacetic acid, the protein precipitates were dis-
solved in 1 ml of 100 mmol/L NaOH, and radioactivities were
determined with a liquid scintillation counter.
2.6. Real-time RT-PCR
Total RNA was isolated from the LV tissues or cultured cells
using TRIZol reagent according to the manufacturer’s instructions.
After purification RNA was subjected to the real-time RT-PCR anal-
ysis for expression of atrial natriuretic peptide (ANP) and skeletal
a-actin (SAA) on a BIO-RAD IQ5 multicolor detection system. Melt-
ing curves and quantization were analyzed using Light Cycler and
Rel Quant software, respectively. A comparative CT method was
used to determine relative quantification of RNA expression. All
PCR reactions were performed at least triplicate.
2.7. Western blot analyses
Total proteins isolated from LV tissues or culture cells were sub-
jected to Western blot analysis for phosphorylation of extracellularsignal-regulated protein kinases (ERKs). The amounts of AT1-R
were examined after dividing the membrane fraction and the cyto-
solic fraction. Briefly, cells were lysed and first centrifuged at 200g
to remove nuclei. The supernatant was centrifuged at 15,000g for
30 min to pellet cell membrane. The total proteins or pelleted
membranes were size-fractionated by SDS–PAGE and transferred
to Immobilon-P membranes (Millipore). The blotted membranes
were incubated with antibodies against phosphorylated ERKs (Cell
Signaling Technology, 9101L) and AT1-R (Santa Cruz Biotechnology,
sc-1173G), and subjected to an ECL Detection system (GE Health-
care, RPN2106).
2.8. Immunofluorescence
Cardiomyocytes cultured on glass cover slides in the presence of
vehicle (Control), AngII (1 lmol/l), HDL (100 lg/ml) or HDL plus
AngII 48 h were incubated with an anti-a-myosin heavy chain
(MHC) (Upstate, catalogue 05-716, USA) antibody and then with
the secondary antibody conjugated with FITC (Invitrogen,
A21206) according to the manufacturer’s directions. The surface
area (SA) of cardiomyocytes stained by anti-a-MHC antibody was
determined with image analysis software (Leica Qwin 3) and calcu-
lated as the mean of 100–120 cells from randomly selected fields.
2.9. Statistical analysis
Data are shown as means ± S.E.M. Comparison was performed
by one-way or two-way analysis of variance followed by New-
man–Keuls test for post hoc analysis to determine the difference
among groups.3. Results
3.1. HDL inhibited hypertrophic responses induced by AngII in cultured
cardiomyocytes
After incubated with [3H] leucine (1 Ci/ml) in the presence of
AngII, HDL, HDL plus AngII or vehicle (Control) for 48 h, the cul-
tured neonatal rat cardiomyocytes were subjected to test the rate
of the cell protein synthesis. AngII significantly increased the pro-
tein synthesis of cardiomyocytes (Fig. 1A). We then measured the
SA of cardiomyocytes by immunostaining using antibody against
a-MHC. Similarly, treatment with AngII increased the SA of cardio-
myocytes by approximately 78% (Fig. 1B). The upregulation of
phosphorylation of ERKs was thought to be an important hypertro-
phic response. We thus examined the phosphorylation levels of
ERKs in AngII-treated cardiomyocytes. The phosphorylation levels
were significantly increased by AngII (Fig. 1C). Similar results were
observed in detection of expression of fetal type genes, ANP and
SAA, both of which were upregulated in AngII-treated cardiomyo-
cytes (Fig. 1D).
Interestingly, addition of HDL to AngII-stimulated cardiomyo-
cytes significantly abrogated all AngII-induced hypertrophic
responses, such as increased cell protein synthesis, enlarged cell
surface area, upregulated p-ERK and reprogrammed fetal type
genes expression (Fig. 1A–D), clearly indicating an in vitro anti-
hypertrophic effect of HDL against AngII.
3.2. HDL inhibited AngII-induced cardiac hypertrophy in vivo
To investigate whether HDL has an anti-hypertrophic effect
in vivo, we treated the mice with low doses of AngII (200 ng/
kg/min), which was insufficient to elevate the BP of mice, HDL
(400 ng/kg/min) or both of them. Two weeks later, although














































































































Fig. 1. Effects of HDL on AngII-induced cardiomyocyte hypertrophy in cultured cardiomyocytes. Cultured cardiomyocytes of neonatal rats were added by vehicle (Control),
AngII (1 lmol/l), HDL (100 lg/ml) or HDL plus AngII for 48 h. (A) [3H]-leucine incorporation in cardiomyocytes. (B) Cardiomyocytes morphology and size. Cardiomyocytes
were subjected to the immunofluorescent staining for a-MHC (green) and DAPI staining. Representative photographs from three independent experiments are shown (scale
bar: 10 lm). Surface area (SA) of cardiomyocytes was evaluated by measuring 100 cardiomyocytes in one dish. (C) Cultured cardiomyocytes of neonatal rats were added by
vehicle (Control), AngII (1 lmol/l), HDL (100 lg/ml) or HDL plus AngII for 8 min. Phosphorylation of ERKs. ERKs were examined by Western blotting using an anti-phosphor-
ERKs antibody. Total ERKs were used as the loading control. Representative photograms from three independent experiments are shown. (D) Cultured cardiomyocytes of
neonatal rats were added by vehicle (Control), AngII (1 lmol/l), HDL (100 lg/ml) or HDL plus AngII for 24 h. Expression of ANP and SAA genes evaluated by the real time RT-
PCR. b-actin was served as internal control. All data are expressed as mean ± S.E.M from three independent experiments. ⁄⁄p < 0.01 vs. cardiomyocytes in Control; ##p < 0.01
vs. cardiomyocytes with AngII. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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developed a significant cardiac hypertrophy including the in-
creased LVAWd (left ventricular anterior wall at end diastole)
and LVPWd (left ventricular posterior wall at end diastole), de-
creased LVIDd (left ventricular internal dimension at end dias-
tole) and preserved LVFS (left ventricular Fractional shortening)
(Fig. 2B). Gross heart size and heart weight to body weight radio
(HW/BW) were also increased by treatment with AngII (Fig. 2C).
Measurement of CSA of cardiomyocytes in H–E stained LV sec-
tions revealed that AngII significantly enlarged the cardiomyo-
cytes size (Fig. 2D). Similar to the results from in vitro
experiments, the upregulation of phosphorylation of ERKs and
expression of SAA and ANP were also observed in the hearts of
AngII-treated mice (Fig. 2E and F).
Consistent with the anti-hypertrophic effect of HDL against the
stimulation with AngII in cultured cardiomyocytes, HDL signifi-
cantly blunted the in vivo cardiac hypertrophy induced by AngII
(Fig. 2A–F), as demonstrated by the thinner ventricular wall, approx-
imately normal ventricular chamber and preserved systolic function
without affecting the BP of mice. The HW/BW ratio and CSA of
myocardiocytes were significantly abrogated by HDL. Moreover,
treatment with HDL significantly inhibited the upregulation of
phosphorylated ERK and SAA and ANP expression induced by AngII.
3.3. HDL inhibited the expression of AT1 receptor in AngII-treated
myocardiocytes
It had been believed that AT1-R plays a critical role in the AngII-
induced cardiac hypertrophy. Hence we tested whether HDL atten-uated the AngII-induced cardiac hypertrophy through inhibition of
AT1-R. We detected the expression of AT1-R in cultured cardio-
myocytes and hearts after AngII treatment by the Western blotting.
AngII treatment significantly induced upregulation of AT1-R
expression both in cultured cardiacmyocytes and hearts and HDL
significantly restrained the increased AT1-R expression, suggesting
that downregulation of AT1-R maybe contribute to the anti-
hypertrophic effects of HDL (Fig. 3).
4. Discussion
Previous studies indicated that HDL as an emerging player in
the field of cardiovascular protection was largely attributed to
it’s key role in reverse cholesterol transport [25]. However, a grow-
ing body of evidence has revealed that HDL possesses several other
potent biological functions, such as anti-inflammatory, anti-oxida-
tive, anti-apoptotic and nitric oxide (NO)-generating properties
independently of reverse cholesterol transport. Such properties
could be of direct benefit for cardiac events [26–30]. Recent studies
have shown that the underlying mechanism for HDL effects may be
to inhibit inflammatory neutrophil recruitment and cardiomyocyte
apoptosis [31]. The present study indicates that administration
with HDL inhibits both in vitro and in vivo cardiomyocyte hypertro-
phy induced by AngII, and our results also suggest that the effect of
HDL on cardiomyocyte hypertrophy is, at least in part, due to inhi-
bition of AT1-R.
AngII plays a critical role in cardiac growth, resulting in in-
creases in cardiac fibrosis, remodeling and dysfunction [32–34].
The present study provides an evidence for HDL to have protective







































































) ** # #
# #








































Control                 AngII              AngII+HDL                HDL   






















































Fig. 2. Inhibition of AngII-induced cardiac hypertrophy by HDL in mice. C57B/L6 mice were infused with vehicle (Control), AngII (200 ng/kg/min), HDL (400 ng/kg/min) or
AngII plus HDL for 2 weeks. (A) BP recordings. Representative recordings from five mice are shown. (B) Echocardiographic analysis. Representative M-mode tracings from five
mice are shown. All echocardiographic measurements are shown as mean ± S.E.M from five mice. LVAWd, LV anterior wall thickness at end-diastole; LVPWd, LV posterior
wall thickness at end-diastole; LVIDd, LV internal dimension at end-diastole; LVFS, LV fraction shortening. (C) Heart morphology and weight. Representative global heart
photographs of five mice are shown (scale bar: 2 mm). Heart weigh to body weight radio (HW/BW) was measured from five mice. (D) H–E stained LV sections of mice. Scale
bar: 20 lm. Cross sectional area (CSA) of cardiomyocyte was measured from five sections for one heart and five hearts were examined. (E) Phosphorylation of ERKs. ERKs were
examined by Western blotting using an anti-phosphor-ERKs antibody. Total ERKs were served as the loading control. Representative photograms from five hearts are shown.
(F) Expression of ANP and SAA genes evaluated by the real time RT- PCR. b-actin was used as internal control. All values are expressed as mean ± S.E.M. of five mice in all
groups. ⁄p < 0.05, ⁄⁄p < 0.01 vs. Control; #p < 0.05, ##p < 0.01 vs. AngII-treated mice.
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mated by the heart weight/body weight ratio, cardiomyocyte area,
echocardiographic measurements, and ANP and SAA mRNA expres-sion, cardiac hypertrophy by AngII infusion for 2 weeks was signif-
icantly formed in mice independently of BP. Administration




Fig. 3. Effects of HDL on expression of AT1-R proteins. Cultured cardiomyocytes and
mice were treated with vehicle, AngII, HDL or AngII plus HDL. Membrane proteins
were extracted from cardiomyocytes and LV of mice and subjected to Western blot
analyses for expression of AT1-R proteins using an anti AT1-R antibody as described
in (Section 2). b-actin in whole cell lysate was used as the loading control.
Representative photograms from three independent experiments for cardiomyo-
cytes or from five hearts of mice are shown.
32 L. Lin et al. / Biochemical and Biophysical Research Communications 404 (2011) 28–33hypertrophic responses. Taken together with our in vitro results
that AngII–induced cardiomyocytes hypertrophy was also attenu-
ated by HDL treatment, our present observations demonstrate that
HDL prevents from AngII-induced cardiac hypertrophy.
Our study reveals a suppression of AngII-increased AT1-R
expression by HDL, suggesting a possible mechanism for HDL ac-
tions. We postulated that the reduction of AT1-R expression by
HDL is a significant mechanism for subsequent reduced cardiac
hypertrophy during AngII stimulation. Under cardiac hypertrophy
condition, the RAS is activated [3]. Given the known protective ef-
fects of HDL [13,35,36], we hypothesized that HDL could also reg-
ulate AT1-R expression under cardiac hypertrophy conditions. To
investigate this hypothesis, we administered HDL via continuous
infusion of HDL into mice and added HDL to cultured cardiomyo-
cytes in the presence of AngII stimulation. Because the expression
level of AT1-R defines the biological efficacy of AngII, HDL-induced
downregulation of AT1-R reflects antagonism of HDL to AngII-
mediated cardiac hypertrophy. Here, the HDL-caused downregula-
tion of AT1-R in cardiomyocytes was in agreement with a decrease
of cardiac hypertrophy. Our finding that HDL reduces AT1R expres-
sion and subsequent AngII–stimulated cardiac hypertrophy is con-
sistent with the recent observation [37], who demonstrated that
HDL inhibited the activation of Rac1, which is a downstream signal
of AngII-stimulated AT1-R activation [38].The exact mechanism by
which HDL suppresses AngII-simulated AT1-R expression during
the development of cardiac hypertrophy requires further funda-
mental studies.
In conclusion, we demonstrate that HDL protects against AngII-
induced cardiac hypertrophy possibly through downregulation of
AT1-R. Our results suggest a possible strategy for the treatment
of cardiac hypertrophy through elevation of HDL levels.
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